Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan · Delayed Price · Currency is TWD 32.30
-0.70 (-2.12%)
Sep 8, 2026, 12:09 PM CST
Pharmosa Biopharm Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 53.38 | 67.27 | 167.57 | 314.5 | - | - | |
Revenue Growth | -69.25% | -59.86% | -46.72% | - | - | - |
Cost of Revenue | 42.79 | 54.24 | 40.67 | - | - | - |
Gross Profit | 10.59 | 13.03 | 126.9 | 314.5 | - | - |
Selling, General & Admin | 49.73 | 49.23 | 50.69 | 40.35 | 29.22 | 18.32 |
Research & Development | 367.65 | 366.65 | 294.79 | 276.97 | 242.31 | 240.81 |
Operating Expenses | 417.38 | 415.89 | 345.47 | 317.32 | 271.53 | 259.12 |
Operating Income | -406.79 | -402.86 | -218.57 | -2.82 | -271.53 | -259.12 |
Interest Expense | -2.57 | -2.1 | -2.42 | -2.86 | -0.65 | -1.21 |
Interest & Investment Income | 22.27 | 29.85 | 32.07 | 9.53 | 0.5 | 0.1 |
Earnings From Equity Investments | -1.2 | -0.9 | 1.95 | 5.5 | 3.93 | 0.66 |
Currency Exchange Gain (Loss) | 36.96 | -7.87 | 19.31 | -6.68 | 1.02 | 0.2 |
Other Non Operating Income (Expenses) | 0 | 0.02 | 1.16 | 5.79 | 0.23 | 2.89 |
EBT Excluding Unusual Items | -351.33 | -383.85 | -166.49 | 8.46 | -266.51 | -256.48 |
Gain (Loss) on Sale of Assets | - | - | -0.34 | - | - | - |
Other Unusual Items | - | - | 0.18 | - | - | - |
Pretax Income | -351.33 | -383.85 | -166.65 | 8.46 | -266.51 | -256.48 |
Net Income | -351.33 | -383.85 | -166.65 | 8.46 | -266.51 | -256.48 |
Net Income to Common | -351.33 | -383.85 | -166.65 | 8.46 | -266.51 | -256.48 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 129 | 129 | 126 | 113 | 99 | 85 |
Shares Outstanding (Diluted) | 129 | 129 | 126 | 113 | 99 | 85 |
Shares Change | 0.04% | 2.12% | 11.49% | 15.09% | 16.02% | 78.34% |
EPS (Basic) | -2.72 | -2.97 | -1.32 | 0.07 | -2.70 | -3.02 |
EPS (Diluted) | -2.72 | -2.97 | -1.32 | 0.07 | -2.70 | -3.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -498.58 | -476.18 | -292.43 | -50.01 | -268.47 | -240.57 |
Free Cash Flow Per Share | -3.86 | -3.69 | -2.31 | -0.44 | -2.73 | -2.83 |
Gross Margin | 19.84% | 19.38% | 75.73% | 100.00% | - | - |
Operating Margin | -762.03% | -598.88% | -130.44% | -0.90% | - | - |
Profit Margin | -658.14% | -570.63% | -99.45% | 2.69% | - | - |
Free Cash Flow Margin | -933.99% | -707.88% | -174.51% | -15.90% | - | - |
EBITDA | -380.64 | -382.04 | -205.09 | 2.99 | -266.24 | -254.73 |
EBITDA Margin | - | - | -122.39% | 0.95% | - | - |
D&A For EBITDA | 26.15 | 20.81 | 13.48 | 5.81 | 5.3 | 4.39 |
EBIT | -406.79 | -402.86 | -218.57 | -2.82 | -271.53 | -259.12 |
EBIT Margin | - | - | -130.44% | -0.90% | - | - |